Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
6 Health Care Dividend Stocks To By Hand Over Fist
10:48am, Monday, 11'th Dec 2023
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
Moderna, Merck begin late-stage study for mRNA cancer therapy
07:01am, Monday, 11'th Dec 2023
Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a ty
Dividend Lovers Betting Big on 6 Goldman Sachs Top Conviction List Picks for 2024
09:12am, Saturday, 09'th Dec 2023
This integrated giant is safer for investors looking to get positioned in the energy sector, has backed up some, and now yields a strong 4.17% dividend.
How To Invest $100,000 Today In A Sleep Well Portfolio
09:00am, Saturday, 09'th Dec 2023
The economic cycles have always been with us. But the frequency of boom and bust cycles has certainly increased in the last couple of decades. If the volatility of the stock market keeps you awake at
Merck-Eisai uterine cancer drug combination fails first-line treatment study
09:31am, Friday, 08'th Dec 2023
Merck & Co Inc (NYSE:MRK) and Eisai announced Friday that their therapeutic combination targeting endometrial cancer as a first-line treatment failed to meaningfully slow the progression of the disea
Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial
07:56am, Friday, 08'th Dec 2023
Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. ESALF, +3.00% said Friday that a late-stage trial of Merck's blockbuster cancer treatment Keytruda in combination with Eisai's drug Lenvima failed to me
Merck-Eisai's cancer therapy combo fails in late-stage study
06:56am, Friday, 08'th Dec 2023
Merck said on Friday its experimental combination therapy being developed with partner Eisai to treat a type of cancer in the lining of the uterus failed to meet the main goals in a late-stage study.
Merck cancels Phase 3 lung cancer study on disappointing interim data as separate mid-stage trial fails
11:33am, Thursday, 07'th Dec 2023
Merck & Co Inc (NYSE:MRK) announced on Thursday that its investigational lung cancer therapeutic combination of pembrolizumab (Keytruda) and vibostolimab failed to meet the goal of a mid-stage study.
Merck's lung cancer drug combo fails to meet trial goal
06:14am, Thursday, 07'th Dec 2023
Merck said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not reach statistical significance in a mid-stage study.
5 Stocks That Recently Increased Their Dividend
09:42am, Tuesday, 05'th Dec 2023
Dividend growth stocks consistently increase their dividend year after year with a 5-year growth rate of 10% or more. Companies must generate strong free cash flow to sustain dividend growth. All 5 of
December Dogs Of The Dow: 3 Buyable, 5 Watchable
07:51am, Monday, 04'th Dec 2023
"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”
17 Ideal Pre-Crash Recovery December Divi-Dogs
04:55pm, Thursday, 30'th Nov 2023
September-October, 2023, Barron's, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 p
Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
04:30pm, Thursday, 30'th Nov 2023
Merck & Co., Inc. (NYSE:MRK ) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Development
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
09:46am, Wednesday, 29'th Nov 2023
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
Merck raises quarterly dividend to 77 cents vs. 73 cents
01:23pm, Tuesday, 28'th Nov 2023
Merck & Co. Inc. MRK said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents.
